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Abstract
Sex hormone-binding globulin (SHBG) is a glycoprotein responsible for the transport and biologic availability of sex steroid
hormones, primarily testosterone and estradiol. SHBG has been associated with chronic diseases including type 2 diabetes
(T2D) and with hormone-sensitive cancers such as breast and prostate cancer. We performed a genome-wide association
study (GWAS) meta-analysis of 21,791 individuals from 10 epidemiologic studies and validated these findings in 7,046
individuals in an additional six studies. We identified twelve genomic regions (SNPs) associated with circulating SHBG
concentrations. Loci near the identified SNPs included SHBG (rs12150660, 17p13.1, p = 1.86102106), PRMT6 (rs17496332, 1p13.3,
p = 1.4610211), GCKR (rs780093, 2p23.3, p = 2.2610216), ZBTB10 (rs440837, 8q21.13, p = 3.4610209), JMJD1C (rs7910927, 10q21.3,
p = 6.1610235), SLCO1B1 (rs4149056, 12p12.1, p = 1.9610208), NR2F2 (rs8023580, 15q26.2, p = 8.3610212), ZNF652 (rs2411984,
17q21.32, p = 3.5610214), TDGF3 (rs1573036, Xq22.3, p = 4.1610214), LHCGR (rs10454142, 2p16.3, p = 1.3610207), BAIAP2L1
(rs3779195, 7q21.3, p = 2.7610208), and UGT2B15 (rs293428, 4q13.2, p = 5.5610206). These genes encompass multiple biologic
pathways, including hepatic function, lipid metabolism, carbohydrate metabolism and T2D, androgen and estrogen receptor
function, epigenetic effects, and the biology of sex steroid hormone-responsive cancers including breast and prostate cancer.
We found evidence of sex-differentiated genetic influences on SHBG. In a sex-specific GWAS, the loci 4q13.2-UGT2B15 was
significant in men only (men p=2.5610208, women p= 0.66, heterogeneity p= 0.003). Additionally, three loci showed strong
sex-differentiated effects: 17p13.1-SHBG and Xq22.3-TDGF3 were stronger in men, whereas 8q21.12-ZBTB10 was stronger in
women. Conditional analyses identified additional signals at the SHBG gene that together almost double the proportion of
variance explained at the locus. Using an independent study of 1,129 individuals, all SNPs identified in the overall or sex-
differentiated or conditional analyses explained ,15.6% and ,8.4% of the genetic variation of SHBG concentrations in men
and women, respectively. The evidence for sex-differentiated effects and allelic heterogeneity highlight the importance of
considering these features when estimating complex trait variance.
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Introduction
Sex hormone-binding globulin (SHBG) is a protein secreted
mainly by the liver that binds to the sex steroids, testosterone,
dihydrotestosterone, and estradiol, transports them in the circu-
lation, and influences their action in target tissues by regulating
their bioavailability. SHBG thereby influences the expression of
sex hormone sensitive phenotypes including sexual characteristics
and reproductive function in men and women [1]. In addition to
regulating sex steroid hormone effects, SHBG may exert
independent effects through its own receptor [2]. Variation in
SHBG concentration has also been associated with various chronic
diseases including cancers [3], polycystic ovary syndrome (PCOS)
[4,5] and type 2 diabetes (T2D) [6,7]. Although SHBG is
estimated to have a heritable component (,50%) [8], little is
known about the genetic regulation of SHBG. Polymorphisms at
the SHBG gene locus have been associated with SHBG concen-
trations [9,10], but much remains unknown about specific genetic
variants that may determine circulating SHBG concentrations.
Identifying genetic factors that influence SHBG may provide
insights into the biology of sex steroid hormone regulation,
metabolism and tissue effects that underlie their relationship with
chronic diseases such as T2D as well as hormone-sensitive cancers
such as breast and prostate cancer.
Results
We identified nine loci associated with SHBG concentrations at
the genome-wide significance threshold of p = 561028 (Table 1
and Figure 1) in a genome-wide association study (GWAS) meta-
analysis of circulating SHBG concentrations in 21,791 men and
women from 10 studies (Table S1). All nine lead SNPs at these loci
had effects in the same direction (seven with p,0.05) in the
validation dataset of 7,046 men and women from six additional
studies (Table S2). The strongest association was within the SHBG
locus (rs12150660, p = 26102106). Together, these nine lead SNPs
explained 7.2% of the genetic variance (assuming 50% heritability)
in SHBG concentrations.
We next performed a series of additional analyses to explain
more of the phenotypic variance (Figure 2). First, we hypothesized
that genetic effects may be different in men and women, as SHBG
concentrations are .50% higher in females than males, and may
be differentially regulated between sexes. In a sex stratified
analysis, three of the nine loci showed evidence of sex-differen-
tiated effects at p,0.02 when we would not expect any signals to
have reached this level of significance by chance. The associations
at the 17p13.1-SHBG and Xq22.3 loci were stronger in males
whereas the association at the 8q21.13 locus was stronger in
females. To investigate the apparent differential sex effect for the
X chromosome further we ran a recessive regression model for the
X chromosome SNP rs1573036 in women in the Framingham
Heart Study and found no association with SHBG suggesting the
sex-differentiated effect is not the result of a recessive inheritance
pattern. Sex stratified GWAS identified one novel signal in men,
which showed no association in women (4q13.2: men
p= 2.561028, women p= 0.66, heterogeneity p= 0.003).
A series of conditional analyses were performed to identify
statistically independent signals. At the SHBG locus, three
apparently independent additional signals separate from the main
index SNP were observed, based on low (r2,0.05) pairwise
correlations in HapMap (rs6258 p=2.7610246, rs1625895
p= 1.2610214 and rs3853894 p=2.5610211). A series of iterative
conditional analyses (Table 2) involving SNPs at the SHBG locus
generated a final regression model including six statistically
independent SHBG SNPs. Four of these SNPs (#1–4 Table 2)
retained GWS when conditioned against the other five, and two
were nominally associated (SNP#5 p= 0.0001, SNP#6 p= 0.01).
Re-running the GWAS meta-analysis adjusting for these six SNPs
revealed evidence for three additional statistically independent
(pairwise HapMap r2,0.01) signals at the SHBG locus (SNP#7
p= 1.561027, SNP#8 p= 4.661025, SNP#9 p= 9.961026)
(Figure 3). There were also two additional trans signals located at
2p16.3 and 7q21.3 (Table 1). Although the 2p16.3 signal dropped
below GWS when combined with follow-up samples (p = 161027),
the index SNP at 2p16.3 is,300 kb away from a strong candidate
gene, the luteinizing hormone receptor gene (LHCGR).
The majority of pair-wise correlations for the nine SHBG locus
SNPs highlighted by our conditional analyses showed very low
HapMap r2 values. However, the pairwise D9 values are often high
(Table S3) indicating that no or few recombination events have
occurred between some SNPs, and that combinations of SNPs
may be tagging un-typed variants on a common haplotype. To
investigate this possibility, we performed more extensive analyses
in a single study (NFBC1966, n = 4467). We used a denser set of
SNPs imputed from the June 2011 version of the 1000 Genomes
data and performed model selection analyses. Model selection
identifies a set of SNPs that best explain phenotypic variation,
while simultaneously penalizing each SNP included in this set, and
therefore correlated SNPs tend to be excluded from the final
model. These analyses consistently included at least seven SNPs in
the model, although it is hard to estimate the false-negative rate of
using the reduced sample size. While we are underpowered to
accurately pinpoint the exact number of independent signals, these
analyses support the results of the conditional analysis and suggest
that multiple variants at the SHBG locus are independently
associated with SHBG concentrations.
Data from an independent study, the InCHIANTI study, was
used to calculate the proportion of genetic variance in SHBG
concentrations explained when accounting for sex specific effects,
the multiple signals of association at the SHBG locus, and the
additional trans signals identified post conditional analysis. In men
and women we explained ,15.6% and ,8.4% of the heritable
Author Summary
Sex hormone-binding globulin (SHBG) is the key protein
responsible for binding and transporting the sex steroid
hormones, testosterone and estradiol, in the circulatory
system. SHBG regulates their bioavailability and therefore
their effects in the body. SHBG has been linked to chronic
diseases including type 2 diabetes and to hormone-
sensitive cancers such as breast and prostate cancer. SHBG
concentrations are approximately 50% heritable in family
studies, suggesting SHBG concentrations are under signif-
icant genetic control; yet, little is known about the specific
genes that influence SHBG. We conducted a large study of
the association of SHBG concentrations with markers in the
human genome in ,22,000 white men and women to
determine which loci influence SHBG concentrations.
Genes near the identified genomic markers in addition to
the SHBG protein coding gene included PRMT6, GCKR,
ZBTB10, JMJD1C, SLCO1B1, NR2F2, ZNF652, TDGF3, LHCGR,
BAIAP2L1, and UGT2B15. These genes represent a wide
range of biologic pathways that may relate to SHBG
function and sex steroid hormone biology, including liver
function, lipid metabolism, carbohydrate metabolism and
type 2 diabetes, and the development and progression of
sex steroid hormone-responsive cancers.
Genetic Influences of Sex Hormone–Binding Globulin
PLoS Genetics | www.plosgenetics.org 4 July 2012 | Volume 8 | Issue 7 | e1002805
T
a
b
le
1
.
SN
P
s
re
p
re
se
n
ti
n
g
lo
ci
as
so
ci
at
e
d
w
it
h
ci
rc
u
la
ti
n
g
SH
B
G
co
n
ce
n
tr
at
io
n
s.
D
is
co
v
e
ry
S
a
m
p
le
s
D
is
co
v
e
ry
+F
o
ll
o
w
-u
p
In
d
e
x
S
N
P
A
n
a
ly
si
s
R
e
g
io
n
N
r
G
e
n
e
C
h
r
P
o
si
ti
o
n
E
ff
e
ct
A
ll
e
le
O
th
e
r
A
ll
e
le
E
A
F
B
e
ta
S
E
p
B
e
ta
S
E
p
rs
1
7
4
9
6
3
3
2
M
ai
n
1
p
1
3
.3
P
R
M
T
6
1
1
0
7
3
4
7
8
9
8
a
g
0
.6
7
2
0
.0
2
6
0
.0
0
4
6
1
.0
E-
0
8
2
0
.0
2
8
0
.0
0
4
1
1
.4
E-
1
1
rs
7
8
0
0
9
3
M
ai
n
2
p
2
3
.3
G
C
K
R
2
2
7
5
9
6
1
0
7
t
c
0
.4
0
2
0
.0
3
3
0
.0
0
4
3
5
.8
E-
1
4
2
0
.0
3
2
0
.0
0
3
9
2
.2
E-
1
6
rs
4
4
0
8
3
7
M
ai
n
8
q
2
1
.1
3
Z
B
T
B
1
0
8
8
1
6
2
4
5
2
9
a
g
0
.7
8
2
0
.0
3
0
0
.0
0
5
2
6
.7
E-
0
9
2
0
.0
2
8
0
.0
0
4
7
3
.4
E-
0
9
rs
7
9
1
0
9
2
7
M
ai
n
1
0
q
2
1
.3
JM
JD
1
C
1
0
6
4
8
0
8
9
1
6
t
g
0
.5
1
2
0
.0
4
4
0
.0
0
4
3
7
.4
E-
2
5
2
0
.0
4
8
0
.0
0
3
9
6
.1
E-
3
5
rs
4
1
4
9
0
5
6
M
ai
n
1
2
p
1
2
.1
SL
C
O
1
B
1
1
2
2
1
2
2
2
8
1
6
t
c
0
.8
2
0
.0
3
2
0
.0
0
5
7
1
.5
E-
0
8
0
.0
2
9
0
.0
0
5
2
1
.9
E-
0
8
rs
8
0
2
3
5
8
0
M
ai
n
1
5
q
2
6
.2
N
R
2
F2
1
5
9
4
5
0
9
2
9
5
t
c
0
.7
2
2
0
.0
2
9
0
.0
0
4
9
2
.8
E-
0
9
2
0
.0
3
0
.0
0
4
4
8
.3
E-
1
2
rs
1
2
1
5
0
6
6
0
M
ai
n
1
7
p
1
3
.1
SH
B
G
1
7
7
4
6
2
6
4
0
t
g
0
.2
4
0
.1
0
0
0
.0
0
5
3
1
.2
E-
7
9
0
.1
0
3
0
.0
0
4
7
1
.8
E-
1
0
6
rs
2
4
1
1
9
8
4
M
ai
n
1
7
q
2
1
.3
2
Z
N
F6
5
2
1
7
4
4
8
0
0
7
5
0
a
g
0
.2
8
0
.0
3
4
0
.0
0
4
9
1
.5
E-
1
2
0
.0
3
3
0
.0
0
4
4
3
.5
E-
1
4
rs
1
5
7
3
0
3
6
M
ai
n
X
q
2
2
.3
T
D
G
F3
2
3
1
0
9
7
0
6
7
2
4
t
c
0
.3
9
0
.0
3
1
0
.0
0
4
3
5
.1
E-
1
3
0
.0
2
8
0
.0
0
3
7
4
.1
E-
1
4
rs
1
0
4
5
4
1
4
2
C
o
n
d
it
io
n
al
2
p
1
6
.3
LH
C
G
R
2
4
8
4
9
9
9
0
3
t
c
0
.6
9
0
.0
2
6
0
.0
0
4
7
2
.8
E-
0
8
0
.0
2
3
0
.0
0
4
4
1
.3
E-
0
7
rs
3
7
7
9
1
9
5
C
o
n
d
it
io
n
al
7
q
2
1
.3
B
A
IA
P
2
L1
7
9
7
8
3
1
2
9
8
a
t
0
.1
7
2
0
.0
3
3
0
.0
0
5
7
1
.2
E-
0
8
2
0
.0
2
8
0
.0
0
5
1
2
.7
E-
0
8
rs
2
9
3
4
2
8
Se
x-
sp
e
ci
fi
c
4
q
1
3
.2
U
G
T
2
B
1
5
4
6
9
6
2
6
3
7
1
a
g
0
.6
9
2
0
.0
2
3
0
.0
0
4
7
1
.6
E-
0
6
2
0
.0
1
9
0
.0
0
4
2
5
.5
E-
0
6
D
is
co
v
e
ry
M
e
n
D
is
co
v
e
ry
+F
o
ll
o
w
-u
p
M
e
n
D
is
co
v
e
ry
W
o
m
e
n
D
is
co
v
e
ry
+F
o
ll
o
w
-u
p
W
o
m
e
n
H
e
te
ro
g
e
n
e
it
y
In
d
e
x
S
N
P
B
e
ta
S
E
p
B
e
ta
S
E
p
B
e
ta
S
E
p
B
e
ta
S
E
p
p
S
e
x
rs
1
7
4
9
6
3
3
2
2
0
.0
2
7
0
.0
0
5
4
9
.6
E-
0
7
2
0
.0
2
7
0
.0
0
5
1
1
.5
E-
0
7
2
0
.0
2
0
.0
0
8
0
.0
0
3
2
0
.0
2
9
0
.0
0
6
7
1
.8
E-
0
5
0
.7
9
Fe
m
al
e
s
rs
7
8
0
0
9
3
2
0
.0
2
9
0
.0
0
5
2
1
.8
E-
0
8
2
0
.0
2
6
0
.0
0
4
9
7
.0
E-
0
8
2
0
.0
4
0
.0
0
7
6
1
.3
E-
0
7
2
0
.0
4
1
0
.0
0
6
3
8
.6
E-
1
1
0
.0
7
Fe
m
al
e
s
rs
4
4
0
8
3
7
2
0
.0
2
1
0
.0
0
6
2
0
.0
0
0
9
2
0
.0
1
9
0
.0
0
5
8
0
.0
0
1
2
0
.0
4
9
0
.0
0
9
3
1
.2
E-
0
7
2
0
.0
4
2
0
.0
0
7
8
7
.2
E-
0
8
0
.0
2
Fe
m
al
e
s
rs
7
9
1
0
9
2
7
2
0
.0
4
9
0
.0
0
5
1
5
.3
E-
2
2
2
0
.0
5
0
0
.0
0
4
8
1
.2
E-
2
5
2
0
.0
3
8
0
.0
0
7
5
6
.4
E-
0
7
2
0
.0
4
6
0
.0
0
6
3
1
.7
E-
1
3
0
.6
3
M
al
e
s
rs
4
1
4
9
0
5
6
0
.0
2
8
0
.0
0
6
7
0
.0
0
0
0
3
0
.0
2
7
0
.0
0
6
3
1
.5
E-
0
5
0
.0
4
9
0
.0
1
0
3
0
.0
0
0
0
0
2
0
.0
3
7
0
.0
0
8
6
1
.7
E-
0
5
0
.3
6
Fe
m
al
e
s
rs
8
0
2
3
5
8
0
2
0
.0
2
4
0
.0
0
5
7
0
.0
0
0
0
2
2
0
.0
2
5
0
.0
0
5
4
5
.1
E-
0
6
2
0
.0
3
8
0
.0
0
8
7
0
.0
0
0
0
1
2
0
.0
3
8
0
.0
0
7
1
7
.8
E-
0
8
0
.1
3
Fe
m
al
e
s
rs
1
2
1
5
0
6
6
0
0
.1
0
6
0
.0
0
6
3
1
.8
E-
6
3
0
.1
1
0
0
.0
0
5
8
3
.7
E-
8
0
0
.0
8
5
0
.0
0
9
4
1
.8
E-
1
9
0
.0
8
7
0
.0
0
7
7
5
.8
E-
3
0
0
.0
2
M
al
e
s
rs
2
4
1
1
9
8
4
0
.0
3
4
0
.0
0
5
8
5
.9
E-
0
9
0
.0
3
4
0
.0
0
5
4
2
.3
E-
1
0
0
.0
3
2
0
.0
0
8
4
0
.0
0
0
1
0
.0
2
9
0
.0
0
7
3
.2
E-
0
5
0
.5
4
M
al
e
s
rs
1
5
7
3
0
3
6
0
.0
4
0
.0
0
4
8
9
.1
E-
1
7
0
.0
3
5
0
.0
0
4
3
2
.8
E-
1
6
0
.0
1
2
0
.0
0
8
3
0
.1
5
0
.0
1
6
0
.0
0
7
0
.0
2
0
.0
2
M
al
e
s
rs
1
0
4
5
4
1
4
2
rs
3
7
7
9
1
9
5
rs
2
9
3
4
2
8
2
0
.0
3
2
0
.0
0
5
6
1
.5
E-
0
8
2
0
.0
2
9
0
.0
0
5
3
2
.5
E-
0
8
2
0
.0
0
5
0
.0
0
8
5
0
.5
7
2
0
.0
0
3
0
.0
0
7
1
0
.6
6
0
.0
0
3
M
al
e
s
A
ll
SN
P
s
ar
e
o
n
th
e
+s
tr
an
d
an
d
p
o
si
ti
o
n
s
ar
e
b
as
e
d
o
n
b
u
ild
3
6
.E
A
F
=
‘e
ff
e
ct
al
le
le
fr
e
q
u
e
n
cy
’.
B
e
ta
u
n
it
s
ar
e
p
e
r-
al
le
le
e
ff
e
ct
e
st
im
at
e
s
in
n
at
u
ra
l
lo
g
tr
an
sf
o
rm
e
d
n
m
o
l/
L.
Se
x
co
lu
m
n
g
iv
e
s
th
e
se
x
w
it
h
th
e
la
rg
e
st
p
e
r-
al
le
le
b
e
ta
e
st
im
at
e
.
M
is
si
n
g
va
lu
e
s
fo
r
co
n
d
it
io
n
al
SN
P
s
as
se
x-
sp
e
ci
fi
c
co
n
d
it
io
n
al
an
al
ys
is
w
as
n
o
t
p
e
rf
o
rm
e
d
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
g
e
n
.1
0
0
2
8
0
5
.t
0
0
1
Genetic Influences of Sex Hormone–Binding Globulin
PLoS Genetics | www.plosgenetics.org 5 July 2012 | Volume 8 | Issue 7 | e1002805
component respectively. The SHBG locus accounted for ,10%
and ,6.6% of the genetic variation in men and women
respectively with the lead SNP in isolation accounting for
,7.8% and ,3.3% of the variation in men and women,
respectively.
We identified genes near the associated SNPs and explored their
biologic relevance to SHBG. The genes associated with identified
SNPs included the SHBG locus (rs12150660, 17p13.1,
p = 1.86102106), PRMT6 (rs17496332, 1p13.3, p= 1.4610211),
GCKR (rs780093, 2p23.3, p = 2.2610216), ZBTB10 (rs440837,
8q21.13, p = 3.4610209), JMJD1C (rs7910927, 10q21.3,
p = 6.1610235), SLCO1B1 (rs4149056, 12p12.1, p= 1.9610208),
NR2F2 (rs8023580, 15q26.2, p= 8.3610212), ZNF652 (rs2411984,
17q21.32, p= 3.5610214), TDGF3 (rs1573036, Xq22.3,
p = 4.1610214), LHCGR (rs10454142, 2p16.3, p= 1.3610207),
BAIAP2L1 (rs3779195, 7q21.3, p = 2.7610208), and UGT2B15
(rs293428, 4q13.2, p= 5.5610206) (Figure 1).
We used the online tool STRING (www.string-db.org) to
perform pathway analyses to explore possible interactions between
the SHBG gene and the proteins encoded by the 11 most plausible
genes nearest the 11 SNPs listed above. There was an interaction
noted between GCKR and JMJD1C which were associated with the
lipoprotein fractions VLDL and HDL, respectively [11]. In an
expanded analysis, we assessed protein interactions among SHBG
and 67 genes within 500 kb of our 11 identified SNPs and
uncovered additional protein interaction pathways. An interaction
between two proteins encoded by GTF2A1L and STON1 was
found; these proteins are co-expressed in testicular germ cells in
the mouse [12]. An interaction between LHCGR and BRI3
encoded proteins that are associated with the G-protein coupled
receptor complex in the human luteinizing hormone receptor was
also identified [13]. Finally, an interaction between LHCGR and
IAPP (amylin) proteins which are components of a ligand/G-
protein receptor/G-protein alpha subunit complex was found
(database: www.reactome.com).
Targeted analysis of two strong candidate genes, hepatocyte
nuclear factor-4a (HNF4a) and peroxisome-proliferating receptor
c (PPARc) did not identify any SNPs at HNF4a but did identify one
SNP, rs2920502, at PPARc that reached statistical significance
(p = 9.961025) and a second SNP at PPARc, rs13081389, that
reached nominal significance (p = 0.01).
Discussion
In total, we identified 12 genomic regions associated with
circulating SHBG concentrations, including extensive allelic
heterogeneity at the SHBG locus itself. Conditional meta-analyses
carried out at the SHBG locus, identified nine genome-wide
significant SNPs with low correlation (r2,0.01) between them.
Two of these signals (rs6258 [10] and rs6259) are missense variants
and two are low frequency variants (MAF ,2%). Furthermore,
rs12150660 is highly correlated (r2.0.95) [10] with a pentanu-
Figure 1. Manhattan plot of the autosomal SNPs identified in the GWA meta-analysis. The Manhattan plot depicts the SNPs identified in
the GWAS analysis labeled with the nearest gene on the plot. The SNP identified on the X chromosome, rs1573036, at Xq22.3, is not included in this
figure.
doi:10.1371/journal.pgen.1002805.g001
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cleotide repeat, which affects SHBG expression in-vitro [14]. To our
knowledge, the magnitude of secondary signals observed at this
locus are the largest seen for any complex trait.
The proportion of genetic variance in SHBG serum concen-
trations explained when accounting for sex specific effects, the
multiple signals of association at the SHBG locus, and the
Figure 2. Summary of the analytic plan.
doi:10.1371/journal.pgen.1002805.g002
Table 2. Statistically independent signals at the SHBG gene locus.
SNP # Model
Conditioned
On SNP # SNP Position
Effect
Allele
Other
Allele EAF Beta SE p-value
Discovery
p-value
Discovery
Beta
1 Full model 2–6 rs12150660 7462640 t g 0.24 0.082 0.005 1.89E-55 1.19E-79 0.10
2 Full model 1,3–6 rs6258 7475403 t c 0.02 20.272 0.017 1.03E-60 2.69E-46 20.2613
3 Full model 1–2,4–6 rs1641537 7486446 t c 0.14 20.064 0.006 1.20E-24 8.19E-39 20.0814
4 Full model 1–3,5–6 rs1625895 7518840 t c 0.12 20.06 0.006 1.75E-21 1.17E-14 20.052
5 Full model 1–4,6 rs6259 7477252 a g 0.11 0.026 0.007 0.0001 1.46E-07 0.0372
6 Full model 1–5 rs10432029 7331393 a g 0.79 0.0136 0.006 0.01 7.52E-16 0.0446
7 Conditional 1–6 rs9901675 7425536 a g 0.05 20.057 0.01 1.46E-07 5.2E-12 20.07
8 Conditional 1–6 rs8077824 7588951 a g 0.02 0.075 0.018 4.58E-05 0.01 0.0451
9 Conditional 1–6 rs9303218 7339386 t c 0.77 0.026 0.006 9,89E-06 1.21E-11 0.0344
All SNPs are on the+strand and positions are based on build 36. EAF = ‘effect allele frequency’. Beta units are per-allele effect estimates in natural log transformed nmol/
L. ‘Full model’ SNPs were all included in a single regression model, where the effect estimates for each SNP are adjusted for the effect of the others in the model.
‘Conditional’ SNPs are SNPs with low pair-wise LD (HapMap r2,0.01) that were identified after conditioning on the full model SNPs.
doi:10.1371/journal.pgen.1002805.t002
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additional trans signals identified post conditional analysis was
,15.6% in men and ,8.4% in women. The SHBG locus
accounted for ,10% and ,6.6% of the genetic variance in men
and women, respectively, with the lead SNP explaining most of the
genetic variation at ,7.8% for men and ,3.3% for women. Thus
additional signals at the SHBG locus identified through conditional
analyses approximately doubled the variance of the trait
explained. While we provide evidence for multiple variants
associated with SHBG concentrations, further studies are needed
to pinpoint the causal loci and functional variants. For the 11
regions outside the SHBG locus, most have biologically plausible
related genes within 300 kb.
Biology of Plausible Genes near Identified SNPs
Several genes near the identified SNPs regulate sex steroid
production and function. The NR2F2 locus (15q26.2) encodes a
nuclear receptor important in testicular Leydig cell function, the
primary source of gonadal testosterone production [15], and has
been linked to male infertility [16]. NR2F2 has also been associated
with estrogen receptor alpha (ERa) signaling and may influence
hormone responsivity in breast cancer [17]. PRMT6 (1p13.3) also
encodes a nuclear receptor regulatory protein that mediates
estrogen signaling as a co-activator of the estrogen receptor [18].
LHCGR (2p16.3) encodes the luteinizing hormone receptor which
was associated with polycystic ovary syndrome (PCOS) in a recent
GWAS [19,20]. PCOS is both a reproductive and metabolic
disorder characterized by higher testosterone serum concentrations
as well as an increased prevalence of obesity, insulin resistance, and
T2D in women. Inappropriate secretion of luteinizing hormone
leads to increased ovarian production of testosterone. Coincident
lower SHBG concentrations contribute to increased bioavailable
testosterone concentrations and the expression of both reproductive
and metabolic phenotypes in PCOS [21,22,23].
The SLCO1B1 locus encodes a liver-specific transporter of
thyroid hormone as well as estrogens which impact liver
production of SHBG [24]. JMJD1C (10q21.3), also known as
TRIP 8 (thyroid hormone receptor interactor protein 8 [25]), may
impact SHBG concentrations via thyroid hormone effects on liver
protein production. Thyroid hormone may alter SHBG produc-
tion through effects on HNF4a which is known to regulate SHBG
transcription [26,27].
Many of the genes identified are involved in carbohydrate and
lipid metabolism and liver function. The GCKR locus (2p23.3)
encodes a protein that regulates glucokinase activity and has been
associated with T2D in several ethnic populations [28,29,30,31].
GCKR has been associated with metabolic and inflammatory traits
including triglyceride concentrations and other lipid fractions
[30,32], fasting plasma glucose [33,34], insulin concentrations,
uric acid, c-reactive protein (CRP), and non-alcoholic fatty liver
disease which are all characteristic of the metabolic syndrome and
T2D [28,35,36,37,38,39,40,41,42]. The SLCO1B1 locus (12p12.1)
codes for a protein, hepatocyte protein anion-transporting
polypeptide 1B1, involved in liver metabolism of both endogenous
and exogenous compounds [43]. Consistent with SLCO1B1’s role
in liver metabolism, the same SNP (rs4149056) has been associated
with circulating bilirubin concentrations in previous GWAS [44].
BAIAP2L1 (7q21.3) encodes a protein important in cytoskeleton
organization [45] that has been associated with the inflammatory
marker CRP in patients with arthritis [46]. BAIAP2L1 is also
known as IRTKS (insulin receptor tyrosine kinase substrate) which
Figure 3. Allelic heterogeneity at the SHBG gene locus. There was significant allelic heterogeneity at the SHBG gene locus. The nine
independent signals identified in the SHBG gene are shown in relation to their position within the gene. All positions based on build 36. Not all genes
are shown.
doi:10.1371/journal.pgen.1002805.g003
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is involved in insulin receptor signaling [47] and may relate to
insulin resistant states including obesity and T2D [48,49,
50,51,52,53,54]. We conducted a targeted analysis of PPARc, a
gene that influences SHBG gene expression in the liver [1,55] and
is associated with T2D [56,57]. Our analysis identified one
significant SNP (rs2920502, p = 9.961025) and a second nomi-
nally significant SNP (rs13081389, p = 0.01) at PPARc. Some of
the identified genes involved in hepatic metabolism of lipids and
carbohydrates may be affect SHBG concentrations indirectly
through effects on the SHBG transcription regulator HNF4a
although HNF4a itself was not identified in this meta-analyses
[27,58,59,60].
The UGT2B15 locus (4q13.2) was significantly associated with
SHBG concentrations in men but not women in this meta-
analysis. UGT2B15 belongs to a family of genes (the UGT2B gene
family) that code for enzymes involved in the metabolism of sex
hormones through glucuronidation which allows for excretion of
sex steroids through the kidney and the gut via bile excretion
[61,62], primary clearance mechanisms for sex steroids [63].
UGT2B15 is involved in the conjugation and inactivation of
testosterone [64]. An association between rs293428 in the
UGT2B15 locus and circulating SHBG concentrations in men is
supported by a previous study demonstrating that a non-
synonymous SNP in UGT2B15 (rs1902023; D85Y) is associated
with serum SHBG concentrations in younger adult men [65].
UGT2B15 is thought to play a significant role in local tissue
inactivation of androgens in androgen dependent prostate cancer
[66,67]. The mechanism behind the influence of genetic variants
in UGT2B15 on SHBG concentrations is unknown, but one may
speculate that UGT2B15 affects the local androgenic environment
in selected tissues, which in turn results in regulation of SHBG
concentrations.
In addition to UGT2B15, three other genes near the identified
SNPs are associated with carcinogenesis, particularly in the
prostate and breast. ZBTB10 (8q21.13), has been linked to breast
cancer [68]. In breast cancer cell lines ZBTB10 is suppressed by
ROS-microRNA27a thereby enhancing ERa alpha expression
and mediating estrogen effects [17]. The ZNF652 (17q21.32) locus
codes for a DNA binding protein thought to act as a tumor
suppressor gene in breast cancer [69,70,71] that is also co-
expressed with the androgen receptor in prostate cancer [72].
TDGF3, teratocarcinoma derived growth factor 3, is the only
significant region identified on the X chromosome ((Xq22.3).
TDGF3 is a pseudogene of TDGF1 located on chromosome 3p23-p21
that has been associated with testicular germ cell tumors [73].
Strengths and Limitations
This GWAS meta-analysis incorporated data from approxi-
mately 22,000 men and women from 16 epidemiologic cohorts.
The overall size of the study yields power but the meta-analysis of
data from different epidemiologic studies requires the inclusion of
different laboratory methods. The different studies used a variety
of assay methodologies to measure serum SHBG concentrations
although the vast majority were immunoassays (Tables S1 and S2,
Text S1) with similar methodologies. Variation introduced by the
use of different SHBG assays would result in loss of statistical
power and likely bias toward the null. Additionally, the majority of
women were post-menopausal as ascertained by self-report in all
studies (Table S1). SHBG concentrations, like testosterone, decline
only slightly across the menopause [74] so adjustment for
menopause status is not necessary. SHBG may also increase with
ovulation and be slightly higher in the luteal versus the follicular
phase of the menstrual cycle in premenopausal women, but most
studies did not collect data on menstrual phase at the time of
SHBG measurement so adjustment for menstrual phase was not
possible [75]. Finally, individuals were not excluded based on
health status, therefore some individuals with chronic conditions
that may affect hepatic production of or clearance of proteins
including SHBG such as liver disease, renal disease, or severe
malnutrition, may have been included in this analysis.
Conclusion
SHBG synthesis in the liver is known to be affected directly or
indirectly by estrogens, androgens and thyroid hormones and has
been observed to be inversely associated with the higher insulin
concentrations characteristic of insulin resistant states such as T2D
[1,6]. In summary, the results of this GWAS reflect these
influences. Three regions map to proteins related to hepatic
function (12p12.1-SLCO1B1 [76], 2p23.3-GCKR [77] and 10q21.3-
JMJD1C [77]). In addition, 2p23.3-GCKR and 7q21.3-BAIAP2L1
[alias insulin receptor tyrosine kinase substrate (IRTKS)] are
involved in susceptibility to T2D [48] and insulin signaling [47],
respectively. Two signals also mapped to loci involved in thyroid
hormone regulation (10q21.3-JMJD1C and 12p12.1-SLCO1B1).
One signal mapped to the receptor for luteinizing hormone
2p16.3-LHCGR [20], the hormone that stimulates testosterone
production. Five regions mapped to genes previously implicated in
androgen and estrogen signaling (1p13.3-PRMT6 [18], 8q21.13-
ZBTB10 [17], 12p12.1-SLCO1B1 [76], 15q26.2-NR2F2 [78],
4q13.2-UGT2B15 [63]).
We have combined a conventional GWAS approach with
detailed additional analyses, including sex stratification, condi-
tional analysis and imputation from 1000 Genomes. Our results
demonstrate that these approaches can lead to an appreciable gain
in heritable variance explained. It does however highlight the
complexity of elucidating individual variant causality through
statistical approaches. In addition to the extensive allelic hetero-
geneity at the SHBG locus, our data identify loci with a role in sex
steroid hormone metabolism, which may help elucidate the role of
sex steroid hormones in disease, particularly T2D and hormone-
sensitive cancers.
Methods
We performed a genome wide association study (GWAS) meta-
analysis of 21,791 individuals (Table S1: 9,390 women, 12,401
men) from ten observational studies. Data from an additional six
studies totaling 7,046 individuals (Table S2: 4,509 women; 2,537
men) were used for validation. The proportion of variance
explained was estimated in an independent study (InCHIANTI,
n = 1,129). The individual study protocols were approved by their
respective institution’s ethics committee/institutional review board
and all participants provided informed consent prior to participa-
tion. Individuals known to be taking hormonal contraceptives or
hormone replacement therapy at time of SHBG measurement
were excluded from analysis. Age, sex and body mass index (BMI)
were included as covariates. After applying standard quality
control measures, imputed genotypes were available for approx-
imately 2.5 M SNPs. See Figure 2 for an overview of the analytic
plan and the Text S1 for further information for individual studies
included in this meta-analysis.
GWAS Conditional Meta-Analysis Steps
Conditional analysis #1. The initial starting point for the
conditional analysis was the four SHBG locus SNPs that all showed
low Hapmap LD (r2,0.05) with each other: rs12150660 (lead
SNP Table 1), rs6258 p= 2.7610246, rs1625895 p=1.2610214
and rs3853894 p=2.5610211. Each cohort fitted a single
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regression model, fitting SHBG concentrations against these four
genome-wide significant SHBG locus SNPs (rs12150660, rs6258,
rs1625895 and rs3853894), in addition to age, sex and BMI. After
meta-analyzing the results from all cohorts, three of the SNPs
retained genome wide significance when regressed against each
other, with the fourth SNP narrowly missing that threshold
(rs3853894, p = 4.161026).
Conditional GWAS#1 (Table 1, conditional analysis). We
next performed a conditional GWAS meta-analysis, where each
study included, as additional covariates to the original analysis plan,
the ten genome-wide significant autosomal SNPs (the eight ‘Main’
signals from Table 1 and the two unique SHBG locus signals
described above in addition to the lead SNP rs12150660: rs6258 and
rs1625895). Three additional signals (independence based on
HapMap r2,0.05) at the SHBG locus reached genome-wide
significance (rs1641537 p=7.8610232, rs6259 p=1.5610212 and
rs10432029 p=361028), giving a total of six independent signals in
this gene region. In addition, two novel signals reached genome-wide
significance in the conditional analysis, at 7q21.3 (rs3779195
p=161028) and 2p16.3 (rs10454142 p=361028). After replication,
only rs3779195 at the BAIAP2L1 locus retained genome-wide
significance.
Conditional analysis #2 (Table 2, full model). Given the
six signals observed at the SHBG locus (three through conditional
analysis #1 rs12150660, rs6258, rs1625895, three through LD
estimates from conditional GWAS #1: rs1641537, rs6259,
rs10432029), we sought to confirm which of these six were truly
independent by a second round of conditional analysis. All
discovery and replication cohorts fitted a single regression model
of the six SNPs (SNPs # 1–6, Table 2) against SHBG
concentrations, using the same parameters and covariates as
conditional analysis #1. Four of the six SNPs (#1–4: rs12150660,
rs6258, rs1641537, and rs1625895) retained genome-wide signif-
icance when conditioned against each other, with two showing
nominal evidence of association (SNP #5 rs6259, p= 0.0001; SNP
#6 rs10432029, p = 0.01).
Conditional GWAS#2 (Table 2, conditionalmodel). Finally,
we performed a second conditional GWAS analysis, adjusting for the
six SHBG locus SNPs which had evidence of association from
conditional analysis #2. All the discovery cohorts were used in this
analysis, in addition to three replication cohorts (total sample size
24,354). This analysis revealed evidence for a further three
independent signals at the SHBG locus (based on HapMap
r2,0.01), SNP #7 rs9901675 p=1.561027, SNP #8 rs8077824
p=4.661025, and SNP #9 rs9393218 p=9.961026.
Sensitivity Analysis—Allelic Heterogeneity at the SHBG
Locus
We performed a sensitivity analysis using samples from the 1966
Northern Finland Birth Cohort (NFBC1966) study to further
investigate allelic heterogeneity at the SHBG locus (Text S1). The
conditional meta-analysis showed evidence for up to nine signals at
the SHBG locus, but it is possible that these signals could be
explaining a much smaller number of causal variants in the region.
Since 1000 Genomes imputation allows us to assess the genetic
variation associated with a phenotype across a much denser set of
markers, it increases our power to detect allelic heterogeneity
within a region. Therefore, 1000 Genomes imputation was carried
out on all the samples in the NFBC1966 study and forward
selection was used to identify the set of SNPs that best explain the
variation in the SHBG phenotype. 1000 Genomes imputation was
carried out using IMPUTE2. The mean genotype probabilities for
each SNP were calculated and used in the model selection step.
Only SNPs 250 kb upstream and 250 kb downstream from the
SHBG locus (7283453–7786700 bp) were used in the analysis. All
SNPs with MAF ,0.1% or an imputation quality score less than
0.4 were excluded from the analysis. In total, 1978 SHBG region
SNPs measured or imputed in 4467 samples from the NFBC1966
study were used in the sensitivity analysis. Forward selection was
implemented in R (version 2.13.0) using the stepAIC package to
estimate the Akaikie Information Criterion (AIC), an inclusion
parameter. Given the high degree of correlation between the SNPs
in this region, we increased the penalty (k) on the number of terms
included in the model to 12 (where it is usually two), to minimize
possible over fitting. The final model included seven SNPs,
adjusted for sex and BMI.
Pathway Analysis
We examined potential interactions among the proteins
encoded by the SHBG locus and the proteins encoded by the 11
genes (ZBT10, TDGF1, ZNF652, PRMT6, JMJD1C, GCKR,
BAIAP2L1, LHCGR, SLCO1B1, UGT2B15, NR2F2) closest to the
11 identified SNPs using pathway analysis with Search Tool for
the Retrieval of Interacting Genes/Proteins (STRING) Pathways
Analysis (www.string-db.org). The interactions explored by
STRING include direct (physical) and indirect (functional)
associations. We then expanded the analysis to examine protein
interactions among the SHBG gene and the proteins encoded by
67 genes within 500 kb of the 11 identified SNPs.
Targeted Candidate Gene Analysis
We conducted targeted analysis of two strong candidate genes,
hepatocyte nuclear factor-4a (HNF4a) and peroxisome-proliferat-
ing receptor c (PPARc). Statistical significance thresholds were set
correcting for the number of SNPs tested in each gene region
(6100 kb).
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